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Abstract 
Gaps in communication between medical officers and poor planning are associated with prescribing errors 
and may result in patient harm. This study describes medication communication on Post Take Ward Rounds 
(PTWR).  
Over 6 weeks on 24 PTWRs, 130 patients, prescribed 1244 medications were observed. Of these, 811(65%) 
medications were discussed, with 249 discussions (relating to 126 medications) being ‘in-depth’. Of 191 
planned medication-related actions, 38 (20%) were not implemented by the end of the PTWR and 21 (11%) 
by time of discharge from hospital. 
This study suggests that the level of medication communication and subsequent actions are 
suboptimal.  Processes to improve this situation should be explored. 
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Introduction 
 
Prescribing, a complex and challenging task, is often suboptimal in hospitals where over- and under-and 
inappropriate prescribing (of drugs or doses) is well recognised(1). This can result in errors and 
unacceptable patient outcomes including a adverse drug events (ADEs) (2).  
 
On Post Take Ward Rounds (PTWR) junior medical officers (JMO) present each patient admitted during 
the previous 24 hours to the admitting unit and its consultant. During this ward round, diagnosis is often 
established and the treating team make decisions about investigations and treatment options, including 
the need for any change in medications(3, 4).  The consultant is responsible for the final management 
decisions, whilst the JMO often implements these decisions including prescribing(5). This separation of 
tasks increases the risk for prescribing errors as JMOs often lack competence and confidence to prescribe 
appropriately(6-8).   
 
Factors contributing to JMOs’ prescribing errors include a lack of drug knowledge, inadequate supervision 
and communication as well as complex patient factors(7). One study identified significant gaps in the 
detail of conversations and inappropriate assumptions made by JMOs’ regarding prescribing (5).  
 
The details of MO communication, decisions and their actioning on the PTWR are poorly understood. 
 
Objectives 
This study aims to describe medication related communication between MOs on internal medicine PTWRs, 
medication decisions made and the extent to which they are implemented.  
The study also investigated whether the discussions focused on medications with higher risk of harm.  
 
Materials and Methods  
 
Study Design 
An observational, prospective, cohort study was conducted where medication related communication 
was observed during daily internal medical PTWRs over a 6-week period in 2014 at a quaternary teaching 
hospital in Brisbane, Australia. At the time of the study, a standard clinical pharmacy service was available 
on weekdays. 
 
Each ward round had a single data collector (trained clinical pharmacist with nine years of hospital 
experience and postgraduate training) whose role was purely observational unless it was felt that an 
intervention was required to prevent or highlight a potential severe error. A data collection tool was 
developed which underwent structured review and user trials to ensure reliability and accuracy of 
documentation regarding prescribing and communication. The data collected was subsequently reviewed 
by a senior pharmacist and senior medical officer to ensure clarity around each data point collected. 
 
Participants 
All members of the eight medical teams provided informed consent to be observed. 
Patients eligible for recruitment were those 16 years or older. For pragmatic reasons, observations 
occurred on a convenience sample of patients seen four days a week from 8am to 11am.   
 
Data Collected 
Data collected included, patient demographics, comorbidities, number of medications prescribed and 
time spent with each patient.  All medication related discussions were recorded and classified as either a 
“Minimal Medication Discussion”, defined as only a mention of the medication and/or the dose, route, 
frequency, monitoring and/or duration or an “In-depth Medication Discussion” where treatment 
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modification was considered. For each discussion, the level of medical officer (consultant, registrar, junior 
medical officer) initiating discussion, and proposing, confirming and implementing the plan were 
recorded.  Any non-medical officers who entered PTWR discussions such as nursing staff and patients 
were classified as “other”. 
 
Subsequent to PTWRs, prescriptions and discharge medication record (DMR) were reviewed, looking for 
evidence of changes to medication that had been proposed on the PTWR. 
 
Data Analysis 
 
All medications were categorised as at high risk of medication related harm according to the Australian 
Safety & Quality Council’s A-PINCH classification system (Antibiotics, Potassium and other electrolytes, 
Insulin and other hypoglycaemic agents, Narcotics and other sedatives, Chemotherapy and Heparin and 
other anticoagulants).(9)  
 
Analysis was undertaken using Microsoft Excel and R (version, publisher, year). Patient demographics and 
other continuous data are presented as mean +/- standard deviation (normal) or as a median (range) for 
non-normal data.  Categorical and binary data have been expressed as counts and percentages of the total 
number of possible outcomes. Chi-squared tests were used to compare proportions between groups (e.g. 
A-PINCH vs. non-A-PINCH). 
 
Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient Cohort 
Patients = 130 
Medications = 1244 
No Medication communication 
or handover  
Patients = 4* 
Medications = 433* 
Medication Communication or 
handover 
Patients = 126 
Medications = 811 
Minimal Medication 
Discussion 
Patients = 26 
Medications = 685 
 
In-depth Medication 
Discussion 
Patients = 100 
Medications = 126 
Discussions = 249 
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Figure One: Flowchart of the frequency of medication discussions on the PTWR. 
* Nil medication communication or handover for 4 of the 130 patients and 433 of the 1244 medications 
across entire cohort (not limited to the 4 patients) 
 
During the 6-week period, 24 PTWRs and 130 patient consultations were observed. Forty-one MOs were 
observed: 11 consultants, 11 registrars and 19 JMOs. There was an average of 4 MOs per PTWR (range 4 
to 6) with a median of 3 observations per team and between 4 and 6 JMOs present on each PTWR. The 
mean duration of a patient review was 23 ±8 minutes (range 7 to 53 minutes).  
 
Of the 130 patients observed, 53% were male and 58% were ≥65 years old; their mean age was 66 years 
(SD 19) The mean number of comorbidities per patient was 6.1 (SD 3.3). The most frequent classifications 
of patients using the Australian Refined Diagnosis Related Group were “Syncope and Collapse” (7), “Chest 
Pain” (6), and “Kidney and Urinary Tract Infection” (6).  
 
For the 130 patient consultations observed, there were 1244 medications charted prior to, or following 
the PTWR, a median of 9 medications per patient (range 0 to 31). Of these, 811 (65.2%) were mentioned 
on the PTWR (see Figure One). A DMR was available for 80 (62%) patients and provided the final list of 
discharge medications. For those patients with a DMR, the median number of medications on discharge 
was 9 per patient (range 1 to 28). 
 
Medication related allergies and ADRs were discussed in 48 (37%) patients and adherence in 19 (14.6%). 
 
Table 1 shows details of the medications discussed for those with “minimal medication discussion” and 
the role of each MO.  
 
Table 1: Medication details mentioned during “minimal medication discussion” (N = 811 medications)  
Aspect discussed Number 
Of 
medications 
Initiated by: 
Consultant Registrar JMO Other 
Medication Name 811 (100%) 90 (11.1%) 567 (69.9%) 116 (14.3%) 38 (0.5%) 
Indication  171 (21.1%) 46  (26.9%) 97 (56.7%) 24 (14.0%) 4  (2.3%) 
Route 27 (3.3%)  16 (59.2%)  11 (40.7%) 0 0 
Dose 226 (27.9%)  43 (19.0%) 144 (63.7%) 32 (14.1%) 7 (3.1%) 
Monitoring 75 (9.2%) 21 (28.0%) 48 (64.0%) 5 (6.7%) 1 (1.3%) 
Duration 41 (5.1%) 9 (22.0%) 23 (56.0%) 6 (14.6%) 3 (7.3%) 
Supply 6 (0.7%) 2 (33.0%) 0 3 (50.0%) 1 (16.7%) 
Frequency 139 (17.1%) 26 (18.7%) 85 (61.1%) 22 (15.8%) 6 (4.3%) 
Note: Number adds to more than 811 as more than one aspect of any medication may have been discussed. 
 
Of the 1244 medications charted prior to or following the PTWR, 30% (n=374) of those mentioned were 
classified as “high risk”, a similar proportion to those that mentioned that were not high risk (30%, n= 
245).  
 
There were 249 in-depth discussions relating to 126 medications, an average of 1.9 per patient. Of these 
249 discussions, 152 (61%) were initiated by the consultant and 78 (31.7%) by the registrar. The 
consultant suggested resolution for 158 (63.4%) of these discussions.  
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Of the 249 in-depth discussions, 58 agreed changes were unable to be actioned on the PTWR, such as 
initiating antibiotic therapy once blood cultures were returned. Of the remaining 191 agreed actions, 153 
(80%) were implemented on the PTWR whilst of the 38 (20%) other actions, only 21 (11%) were ever 
actioned. Of the 153 implemented, 93 (60.8%) of the recommendations were carried out by registrars 
and 51 (33.3%) by JMO’s. 
 
Discussion 
This study has identified a number of clinical gaps in medication communication and implementation of 
agreed medication-related management decisions.  
 
Importantly, less than two-thirds of all prescribed medications were even mentioned on the PTWR, with 
only 10% being discussed in detail. Given that there was no difference in the degree of communication 
dependent on the A-PINCH criteria for high risk medications, it is unlikely that it was merely the less 
important medications that were not discussed (e.g. aperients).  This lack of in-depth discussion suggests a 
missed opportunity to review whether patients’ medications taken prior to admission may have been 
associated with an ADE or have contributed to that admission.  
This study suggests there is an opportunity to enhance medication communication and prescribing 
effectiveness on the PTWR. 
 
Of concern, one in ten clinical decisions made on the PTWR were not implemented, with potential 
adverse patient outcomes. For example, it was agreed to start oral anticoagulants in one patient with 
atrial fibrillation who was clinically indicated for this treatment via a high CHADVSAC2 score and low 
HASBLED score. This did not occur during the admission and or recommended on discharge.  Registrars 
were the most common participant to mention or handover medications on the PTWR however 
consultants were most likely to make treatment decisions.  JMOs are often responsible for implementing 
decisions, but rarely discussed medications on the PTWR in this study.  It is possible that JMO 
disengagement from these conversations has contributed to decisions not being appropriately 
implemented. 
 
Of the medications discussed, rarely were indication and dose mentioned. These are important 
components of the medication review and reconciliation processes which if not undertaken effectively 
may result an adverse outcome(10).  Medication related allergies and ADRs, as well as patient adherence 
were infrequently discussed, in spite of increasing evidence that adherence is positively linked to overall 
health costs (11), rate of hospitalisations(12) and health outcomes(13).  
 
Previous studies suggest a lack of complete medication review during ward rounds which may be due to 
insufficient time allocated to this task(14). This would not appear to be the case in this study where an 
average of 23 (SD 8) minutes spent discussing medication on each patient.  
 
Overall, our findings suggest limited consideration was given in the PTWR setting regarding when 
medications outcomes should be monitored, reviewed and/or stopped. This study highlights the 
opportunity for a system change to improve communication, prioritisation and actioning of medication 
related decisions in order to optimise care on the PTWR. For example, participation of a medication-
focused clinician using a structured medication review tool such as the “Considerate checklist” suggested 
by Mohan et al in the United Kingdom, (4) or the “Medication Management Plan”: an Australian 
Commission on Safety and Quality in Health Care initiative(15). Use of such standardised tools is intended 
to ensure a comprehensive patient review through recording and reconciliation of patients’ medications. 
 
Conclusions 
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This study extends existing knowledge on medication discussions and prescribing on PTWRs. Several 
areas where patient outcomes may be improved are worthy of exploration. 
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